PMID- 36840762
OWN - NLM
STAT- MEDLINE
DCOM- 20230615
LR  - 20230616
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 72
IP  - 7
DP  - 2023 Jul
TI  - Effectiveness and tolerability of camrelizumab combined with molecular targeted 
      therapy for patients with unresectable or advanced HCC.
PG  - 2137-2149
LID - 10.1007/s00262-023-03404-8 [doi]
AB  - There is a lack of effective programmed cell death protein 1 (PD-1)-targeted 
      immunotherapy with good tolerability in patients with advanced hepatocellular 
      carcinoma (HCC) and severely compromised liver function. We assessed patient 
      outcomes after combined camrelizumab and molecular targeted therapy in a 
      multicenter cohort study in China. The study included 99 patients with advanced 
      HCC (58 Child-Pugh A and 41 Child-Pugh B), 84 of them received camrelizumab 
      combined with molecular targeted therapy from January 10, 2019, to March 31, 
      2021. Overall survival (OS), progression-free survival (PFS), objective response 
      rate (ORR), disease control rate (DCR), and adverse events (AEs) were assessed. 
      The median follow-up was 12.1 months. For patients with Child-Pugh B, the OS 
      probability at 12-months, ORR and DCR were 49.7%, 31.7% and 65.9%, respectively, 
      and the median PFS was 5.1 months [95% confidence interval (CI) 3.0-7.1], which 
      were comparable with Child-Pugh A patients, although median OS was shorter in 
      Child-Pugh B patients (20.5 vs.13.4 months, P = 0.12). In multivariate analysis, 
      macrovascular infiltration (MVI), but not sex, age, hepatitis B virus etiology, 
      extrahepatic metastasis, Child-Pugh B, or AFP > 400 ng/ml, was associated with 
      12-months OS [hazard ratio (HR) 2.970, 95% CI 1.276-6.917, P = 0.012] and ORR (HR 
      2.906, 95% CI 1.18-7.16, P = 0.020). Grade 3/4 immune-related AEs occurred in 
      26.8% of Child-Pugh B patients, including one potentially treatment-related 
      death. In both groups, the most common AEs were immune thrombocytopenia and 
      hepatotoxicity. Camrelizumab combined with targeted therapy showed favorable 
      effectiveness and tolerability with manageable toxicities in Chinese HCC 
      patients, regardless of Child-Pugh A/B liver function. MVI was associated with 
      suboptimal immunotherapy response and poor prognosis.
CI  - (c) 2023. The Author(s).
FAU - Li, Ting
AU  - Li T
AD  - Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an 
      Jiaotong University, No. 157 Xi Wu Road, Xi'an, 710004, Shaanxi Province, China.
FAU - Guo, Jiang
AU  - Guo J
AD  - Department of Oncology Interventional Radiology, Beijing Ditan Hospital, Capital 
      Medical University, Beijing, 100015, China.
FAU - Liu, Yushen
AU  - Liu Y
AD  - Department of Infectious Diseases, Tangdu Hospital, the Fourth Military Medical 
      University, Xi'an, 710038, China.
FAU - Du, Zhaoqing
AU  - Du Z
AD  - Department of Hepatobiliary Surgery, Shaanxi Provincial People's Hospital, Xi'an, 
      710068, China.
FAU - Guo, Zhaoyang
AU  - Guo Z
AD  - Department of Infectious Disease, Shandong Provincial Hospital, Shandong 
      University, Jinan, 250021, Shandong, China.
FAU - Fan, Yangwei
AU  - Fan Y
AD  - Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, Shaanxi, China.
FAU - Cheng, Long
AU  - Cheng L
AD  - Department of Oncology Interventional Radiology, Beijing Ditan Hospital, Capital 
      Medical University, Beijing, 100015, China.
FAU - Zhang, Yue
AU  - Zhang Y
AD  - Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an 
      Jiaotong University, No. 157 Xi Wu Road, Xi'an, 710004, Shaanxi Province, China.
FAU - Gao, Xu
AU  - Gao X
AD  - Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an 
      Jiaotong University, No. 157 Xi Wu Road, Xi'an, 710004, Shaanxi Province, China.
FAU - Zhao, Yunyu
AU  - Zhao Y
AD  - Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an 
      Jiaotong University, No. 157 Xi Wu Road, Xi'an, 710004, Shaanxi Province, China.
FAU - He, Xinyuan
AU  - He X
AD  - Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an 
      Jiaotong University, No. 157 Xi Wu Road, Xi'an, 710004, Shaanxi Province, China.
FAU - Wu, Wenhua
AU  - Wu W
AD  - Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an 
      Jiaotong University, No. 157 Xi Wu Road, Xi'an, 710004, Shaanxi Province, China.
FAU - Gao, Ning
AU  - Gao N
AD  - Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an 
      Jiaotong University, No. 157 Xi Wu Road, Xi'an, 710004, Shaanxi Province, China.
FAU - Wu, Yinying
AU  - Wu Y
AD  - Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, Shaanxi, China.
FAU - Li, Jie
AU  - Li J
AD  - Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated 
      Hospital of Nanjing University Medical School, Nanjing, 210008, China.
FAU - Zhang, Yu
AU  - Zhang Y
AD  - Department of Hepatobiliary Surgery, Shaanxi Provincial People's Hospital, Xi'an, 
      710068, China.
FAU - Kang, Wen
AU  - Kang W
AD  - Department of Infectious Diseases, Tangdu Hospital, the Fourth Military Medical 
      University, Xi'an, 710038, China.
FAU - Cai, Zhifang
AU  - Cai Z
AD  - Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an 
      Jiaotong University, No. 157 Xi Wu Road, Xi'an, 710004, Shaanxi Province, China.
FAU - Wang, Wenjun
AU  - Wang W
AD  - Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an 
      Jiaotong University, No. 157 Xi Wu Road, Xi'an, 710004, Shaanxi Province, China.
FAU - Li, Xiaopeng
AU  - Li X
AD  - Department of Ultrasound, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, 710004, China.
FAU - Zan, Ying
AU  - Zan Y
AD  - Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong 
      University, No.157 Xi Wu Road, Xi'an, 710004, Shaanxi Province, China. 
      m13319223009@163.com.
FAU - Nguyen, Mindie H
AU  - Nguyen MH
AUID- ORCID: 0000-0002-6275-4989
AD  - Division of Gastroenterology and Hepatology, Stanford University Medical Center, 
      750 Welch Road, Suite 210, Palo Alto, CA, 94304, USA. mindiehn@stanford.edu.
AD  - Department of Epidemiology and Population Health, Stanford University, Palo Alto, 
      CA, USA. mindiehn@stanford.edu.
FAU - Ji, Fanpu
AU  - Ji F
AUID- ORCID: 0000-0002-1463-8035
AD  - Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an 
      Jiaotong University, No. 157 Xi Wu Road, Xi'an, 710004, Shaanxi Province, China. 
      jifanpu1979@163.com.
AD  - National and Local Joint Engineering Research Center of Biodiagnosis and 
      Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 
      China. jifanpu1979@163.com.
AD  - Key Laboratory of Environment and Genes Related to Diseases, Xi'an Jiaotong 
      University, Ministry of Education of China, Xi'an, China. jifanpu1979@163.com.
LA  - eng
GR  - No.2022SF-451/Natural Science Foundation of Shaanxi Province/
GR  - No.82170626/National Natural Science Foundation of China/
PT  - Journal Article
PT  - Multicenter Study
DEP - 20230225
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 73096E137E (camrelizumab)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular/pathology
MH  - *Liver Neoplasms/pathology
MH  - Molecular Targeted Therapy
MH  - Cohort Studies
PMC - PMC10264531
OTO - NOTNLM
OT  - Camrelizumab
OT  - Child-Pugh B
OT  - Effectiveness
OT  - Hepatocellular carcinoma
OT  - Programmed cell death protein-1
OT  - Tolerability
COIS- Author's declaration of personal interests: Mindie H. Nguyen: Grants: Gilead, 
      Pfizer, Enanta, Vir, Glycotest, National Cancer Institute, B. K. Kee Foundation, 
      Exact Sciences; Helio Health; Consulting or advisory board: Intercept, Gilead, 
      Exact Sciences, Laboratory of Advanced Medicine, Bayer, Eisai, GSK, Novartis. 
      Fanpu Ji: Speaker: Gilead Sciences, MSD and Ascletis. Consulting or advisory 
      board: Gilead Sciences and MSD. All other authors do not have conflict of 
      interest.
EDAT- 2023/02/26 06:00
MHDA- 2023/06/15 06:42
PMCR- 2023/02/25
CRDT- 2023/02/25 11:15
PHST- 2022/06/13 00:00 [received]
PHST- 2023/02/09 00:00 [accepted]
PHST- 2023/06/15 06:42 [medline]
PHST- 2023/02/26 06:00 [pubmed]
PHST- 2023/02/25 11:15 [entrez]
PHST- 2023/02/25 00:00 [pmc-release]
AID - 10.1007/s00262-023-03404-8 [pii]
AID - 3404 [pii]
AID - 10.1007/s00262-023-03404-8 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2023 Jul;72(7):2137-2149. doi: 
      10.1007/s00262-023-03404-8. Epub 2023 Feb 25.